Zhang L, Zhao MH, Zuo L, Wang Y, Yu F, Zhang H, et al. China Kidney Disease Network (CK-NET) 2016 annual data report. Kidney Int Suppl. 2020;10:e97-185.

Article  Google Scholar 

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0158765.

Article  PubMed  PubMed Central  Google Scholar 

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.

Article  PubMed  Google Scholar 

Bello AK, Okpechi IG, Osman MA, Cho Y, Cullis B, Htay H, et al. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022;18:779–93.

Article  PubMed  PubMed Central  Google Scholar 

Zhang W, Shi W, Liu Z, Gu Y, Chen Q, Yuan W, et al. A nationwide cross-sectional survey on prevalence, management and pharmacoepidemiology patterns on hypertension in Chinese patients with chronic kidney disease. Sci Rep. 2016;6:38768.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–14.

Article  CAS  PubMed  Google Scholar 

Smith KR, Hsu CC, Berei TJ, Aldemerdash A, Hollis IB, Vardeny O, et al. PARADIGM-HF trial: secondary analyses address unanswered questions. Pharmacotherapy. 2018;38:284–98.

Article  PubMed  Google Scholar 

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138:1505–14.

Article  CAS  PubMed  Google Scholar 

Jering KS, Zannad F, Claggett B, McCausland FR, Ferreira JP, Desai A, et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021;9:13–24.

Article  PubMed  Google Scholar 

Yang X, Jin J, Cheng M, Xu J, Bai Y. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis. Ren Fail. 2024;46:2349135.

Article  PubMed  PubMed Central  Google Scholar 

Lu H, Claggett BL, Packer M, Lam CSP, Swedberg K, Rouleau J, et al. Effects of sacubitril/valsartan on all-cause hospitalizations in heart failure: post hoc analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials. JAMA Cardiol. 2024;9(11):1047–52.

Article  PubMed  PubMed Central  Google Scholar 

He Y, Jin Y, Xue H, Liu R, Zhang M, Liao R, et al. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients. Nephrol Dial Transplant. 2023;38:1880–9.

Article  CAS  PubMed  Google Scholar 

Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet. 2017;56:1461–78.

Article  CAS  PubMed  Google Scholar 

Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051–65.

Article  PubMed  Google Scholar 

Sinha J, Al-Sallami HS, Duffull SB. An extension of Janmahasatian’s fat-free mass model for universal application across populations of different ethnicities. Clin Pharmacokinet. 2020;59:1161–70.

Article  PubMed  Google Scholar 

Yang H, Gao R, Ji X, Wang Z, Qiu W. Population pharmacokinetic analysis of valsartan in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2023;12:249–56.

Article  CAS  PubMed  Google Scholar 

Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther. 2016;34:191–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marier JF, Teuscher N, Mouksassi MS. Evaluation of covariate effects using forest plots and introduction to the coveffectsplot R package. CPT Pharmacomet Syst Pharmacol. 2022;11:1283–93.

Article  CAS  Google Scholar 

Xanthopoulos A, Papamichail A, Briasoulis A, Loritis K, Bourazana A, Magouliotis DE, et al. Heart failure in patients with chronic kidney disease. J Clin Med. 2023;12:6105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carlson S, Duber HC, Achan J, Ikilezi G, Mokdad AH, Stergachis A, et al. Capacity for diagnosis and treatment of heart failure in sub-Saharan Africa. Heart. 2017;103:1874–9.

Article  PubMed  Google Scholar 

Habtemariam B, Sallas W, Sunkara G, Kern S, Jarugula V, Pillai G. Population pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinet. 2009;24:145–52.

Article  CAS  PubMed  Google Scholar 

Han Y, Ayalasomayajula S, Pan W, Yang F, Yuan Y, Langenickel T, et al. Pharmacokinetics, safety and tolerability of sacubitril/valsartan (LCZ696) after single-dose administration in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2017;42:109–16.

Article  CAS  PubMed  Google Scholar 

Yu H, Greasley PJ, Lambers Heerspink HJ, Ambery P, Ahlstrom C, Hamren B, et al. The role of venous capacity in fluid retention with endothelin A antagonism: mathematical modelling of the RADAR trial. Br J Pharmacol. 2024;181:4693–707.

Article  CAS  PubMed  Google Scholar 

Nguyen DV, Pham GT, Pham SN, Nguyen HTT. Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis. J Hypertens. 2025;43:557–67.

Article  CAS  PubMed  Google Scholar 

Niu CY, Yang SF, Ou SM, Wu CH, Huang PH, Hung CL, et al. Sacubitril/valsartan in patients with heart failure and concomitant end-stage kidney disease. J Am Heart Assoc. 2022;11:e026407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56:78–86.

Article  CAS  PubMed  Google Scholar 

Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998;19:237–44.

Article  CAS  PubMed  Google Scholar 

Hsiao HL, Langenickel TH, Greeley M, Roberts J, Zhou W, Pal P, et al. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clin Pharmacol Drug Dev. 2015;4:407–17.

Article  CAS  PubMed  Google Scholar 

Gan L, Jiang X, Mendonza A, Swan T, Reynolds C, Nguyen J, et al. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clin Pharmacol Drug Dev. 2016;5:27–39.

Article  CAS  PubMed  Google Scholar 

Ayalasomayajula SP, Langenickel TH, Jordaan P, Zhou W, Chandra P, Albrecht D, et al. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. Eur J Clin Pharmacol. 2016;72:1065–73.

Article  CAS  PubMed  Google Scholar 

Judge PK, Herrington WG, Haynes R. Sacubitril/valsartan in peritoneal dialysis-lessons from a pharmacokinetic study. Nephrol Dial Transplant. 2023;38:1780–1.

Article